Background: There were no published data regarding the clinical efficacy and safety of second generation drug-eluting stent (zotarolimus-eluting stent with biolinx polymer, ZES-BP, Endeavor resolute) following primary percutaneous coronary intervention (PCI) in ST-elevation myocardial infarction (STEMI). We evaluated the one-year outcome of zotarolimus-eluting stent with biolinx polymer versus to 1st generation (sirolimus-eluting stent, SES and paclitaxel-eluting stent, PES) and 2nd generation (zotarolimus-eluting stent, ZES and everolimus-eluting stent, EES) drug-eluting stents(DES) for the treatment of STEMI.
Background: Several clinical and angiographic scores have been proposed for the prediction of the outcome of patients with myocardial infarction undergoing primary percutaneous coronary angiography (PCI). The aim of this study was to assess the ability of Clinical Syntax Score (CSS) for predicting outcome late after successful primary PCI. Methods: 345 consecutive patients that underwent successful primary PCI due to STEMI in our hospital were recruited out of 361 primary PCIs. CSS was calculated for each patient as previously described. The patients were followed by outpatient visit or telephone for 2 years. Endpoints included all-cause death, cardiac death, repeat revascularization (RR), stent thrombosis (ST) and major adverse cardiac event (MACE), defined as the composite of death, myocardial infarction, or target vessel revascularization. Results: The median follow-up period was 476 days (mean 496Ϯ5 days). 
